246 related articles for article (PubMed ID: 28942182)
1. Mutational signatures efficiently identify different mutational processes underlying cancers with similar somatic mutation spectra.
Zhou N; Yuan Y; Long X; Wu C; Bao J
Mutat Res; 2017 Dec; 806():27-30. PubMed ID: 28942182
[TBL] [Abstract][Full Text] [Related]
2. Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro.
Baker SC; Mason AS; Southgate J
Eur Urol; 2020 Aug; 78(2):143-147. PubMed ID: 32349929
[TBL] [Abstract][Full Text] [Related]
3. A potential prognostic lncRNA signature for predicting survival in patients with bladder urothelial carcinoma.
Bao Z; Zhang W; Dong D
Oncotarget; 2017 Feb; 8(6):10485-10497. PubMed ID: 28060759
[TBL] [Abstract][Full Text] [Related]
4. Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.
Poulos RC; Wong YT; Ryan R; Pang H; Wong JWH
PLoS Genet; 2018 Nov; 14(11):e1007779. PubMed ID: 30412573
[TBL] [Abstract][Full Text] [Related]
5. Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair.
Phillips DH
DNA Repair (Amst); 2018 Nov; 71():6-11. PubMed ID: 30236628
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.
Poon SL; Pang ST; McPherson JR; Yu W; Huang KK; Guan P; Weng WH; Siew EY; Liu Y; Heng HL; Chong SC; Gan A; Tay ST; Lim WK; Cutcutache I; Huang D; Ler LD; Nairismägi ML; Lee MH; Chang YH; Yu KJ; Chan-On W; Li BK; Yuan YF; Qian CN; Ng KF; Wu CF; Hsu CL; Bunte RM; Stratton MR; Futreal PA; Sung WK; Chuang CK; Ong CK; Rozen SG; Tan P; Teh BT
Sci Transl Med; 2013 Aug; 5(197):197ra101. PubMed ID: 23926199
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases.
He RQ; Zhou XG; Yi QY; Deng CW; Gao JM; Chen G; Wang QY
Cell Physiol Biochem; 2018; 48(3):1355-1368. PubMed ID: 30048970
[TBL] [Abstract][Full Text] [Related]
8. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
9. Bioinformatic Methods to Identify Mutational Signatures in Cancer.
Islam SMA; Alexandrov LB
Methods Mol Biol; 2021; 2185():447-473. PubMed ID: 33165866
[TBL] [Abstract][Full Text] [Related]
10. Patterns and processes of somatic mutations in nine major cancers.
Jia P; Pao W; Zhao Z
BMC Med Genomics; 2014 Feb; 7():11. PubMed ID: 24552141
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.
Olivieri M; Ferro M; Terreri S; Durso M; Romanelli A; Avitabile C; De Cobelli O; Messere A; Bruzzese D; Vannini I; Marinelli L; Novellino E; Zhang W; Incoronato M; Ilardi G; Staibano S; Marra L; Franco R; Perdonà S; Terracciano D; Czerniak B; Liguori GL; Colonna V; Fabbri M; Febbraio F; Calin GA; Cimmino A
Oncotarget; 2016 Apr; 7(15):20636-54. PubMed ID: 26943042
[TBL] [Abstract][Full Text] [Related]
12. Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients.
Fantini D; Seiler R; Meeks JJ
Urol Oncol; 2019 Nov; 37(11):818-825. PubMed ID: 30446446
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive RNA Expression Signature for Cervical Squamous Cell Carcinoma Prognosis.
Xiong J; Guo S; Bing Z; Su Y; Guo L
Front Genet; 2018; 9():696. PubMed ID: 30662454
[TBL] [Abstract][Full Text] [Related]
14. Deciphering signatures of mutational processes operative in human cancer.
Alexandrov LB; Nik-Zainal S; Wedge DC; Campbell PJ; Stratton MR
Cell Rep; 2013 Jan; 3(1):246-59. PubMed ID: 23318258
[TBL] [Abstract][Full Text] [Related]
15. The repertoire of mutational signatures in human cancer.
Alexandrov LB; Kim J; Haradhvala NJ; Huang MN; Tian Ng AW; Wu Y; Boot A; Covington KR; Gordenin DA; Bergstrom EN; Islam SMA; Lopez-Bigas N; Klimczak LJ; McPherson JR; Morganella S; Sabarinathan R; Wheeler DA; Mustonen V; ; Getz G; Rozen SG; Stratton MR;
Nature; 2020 Feb; 578(7793):94-101. PubMed ID: 32025018
[TBL] [Abstract][Full Text] [Related]
16. Understanding mutagenesis through delineation of mutational signatures in human cancer.
Petljak M; Alexandrov LB
Carcinogenesis; 2016 Jun; 37(6):531-40. PubMed ID: 27207657
[TBL] [Abstract][Full Text] [Related]
17. BLCA-4 and UBC combined detection for early diagnosis of bladder cancer.
Cui L; Sun MM; Zhao ZH; Yang JP; Zheng YP; He LL; Chen KS; Fan QX
J Biol Regul Homeost Agents; 2016; 30(2):485-90. PubMed ID: 27358136
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology.
Myers-Irvin JM; Van Le TS; Getzenberg RH
Cancer Res; 2005 Aug; 65(16):7145-50. PubMed ID: 16103064
[TBL] [Abstract][Full Text] [Related]
19. Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
Koutros S; Rao N; Moore LE; Nickerson ML; Lee D; Zhu B; Pardo LA; Baris D; Schwenn M; Johnson A; Jones K; Garcia-Closas M; Prokunina-Olsson L; Silverman DT; Rothman N; Dean M
Clin Cancer Res; 2021 Jul; 27(13):3725-3733. PubMed ID: 33849962
[TBL] [Abstract][Full Text] [Related]
20. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J; Mouw KW; Polak P; Braunstein LZ; Kamburov A; Kwiatkowski DJ; Rosenberg JE; Van Allen EM; D'Andrea A; Getz G
Nat Genet; 2016 Jun; 48(6):600-606. PubMed ID: 27111033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
